Future Experimentation Sample Clauses

Future Experimentation. To properly understand the mechanistic action and individual variability within the sex differences seen in the rapid tolerance to the anxiolytic effects of alcohol, further experiments are required to best understand the nuance of this dimorphic phenomenon. An important step and process to understand within this phenomenon is how allopregnanolone (allo) levels change the severity of the increase following a first or second dose of ethanol. Because the data from the allo immunoassay was inconclusive in this experiment, there was a lack of clarity within the specific hormonal levels seen in the animals. Looking at the specific hormonal levels would allow us to confirm the estrous status approximated vaginal lavage cell composition. Additionally, we would be able to monitor the increases of allo following ethanol consumption. By taking tail bloods, and looking at specific time points following alcohol consumption, we could see the dynamics of the increase of allo. Also, by looking at the differences between the response of allo in regard to either the first or second dose of ethanol could help to elucidate specific differences that arise from the varying increases of allo. This would also help us to understand the potential role of allo in the rapid sensitization to the anxiolytic effects of ethanol in males. Another important aspect is the brain concentration and alterations in the composition of allo and the ∂GABAAR. By using immunohistochemistry and an allo antibody, we could see the occurrences of allo in the brain and the interactions with PV+ interneurons and activated neurons in the basolateral amygdala (BLA). Studies have shown that the concentration of allo differs between the brain and the periphery, specifically in the blood plasma (Bortolato et al., 2011). In order to accurately understand the role that neuroactive steroids play in the brain, it is important to accurately gauge the concentration and location of allo in regard to the receptor it is most sensitive to in the region of the brain that is responsible for the phenomenon we are looking at. Correlation between presence of activated PV+ interneurons and allo in the extracellular space could help to explain the functioning of this system and the development of this rapid tolerance or rapid sensitization. To understand the necessity of the BLA in the function and development of the rapid changes to the anxiolytic effects of ethanol, we would use a cannula implantation stereotaxic surgery for...
AutoNDA by SimpleDocs

Related to Future Experimentation

  • For Product Development Projects and Project Demonstrations  Published documents, including date, title, and periodical name.  Estimated or actual energy and cost savings, and estimated statewide energy savings once market potential has been realized. Identify all assumptions used in the estimates.  Greenhouse gas and criteria emissions reductions.  Other non-energy benefits such as reliability, public safety, lower operational cost, environmental improvement, indoor environmental quality, and societal benefits.  Data on potential job creation, market potential, economic development, and increased state revenue as a result of the project.  A discussion of project product downloads from websites, and publications in technical journals.  A comparison of project expectations and performance. Discuss whether the goals and objectives of the Agreement have been met and what improvements are needed, if any.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Reverse Engineering The Customer must not reverse assemble or reverse compile or directly or indirectly allow or cause a third party to reverse assemble or reverse compile the whole or any part of the software or any products supplied as a part of the Licensed System.

  • Additional Information for Product Development Projects Outcome of product development efforts, such copyrights and license agreements. • Units sold or projected to be sold in California and outside of California. • Total annual sales or projected annual sales (in dollars) of products developed under the Agreement. • Investment dollars/follow-on private funding as a result of Energy Commission funding. • Patent numbers and applications, along with dates and brief descriptions.  Additional Information for Product Demonstrations: • Outcome of demonstrations and status of technology. • Number of similar installations. • Jobs created/retained as a result of the Agreement.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Curriculum Development This includes the analysis and coordination of textual materials; constant review of current literature in the field, some of which are selected for the college library collection, the preparation of selective, descriptive materials such as outlines and syllabi; conferring with other faculty and administration on curricular problems; and, the attendance and participation in inter and intra-college conferences and advisory committees.

  • Development cooperation 1. The Parties recognise that development cooperation is a crucial element of their Partnership and an essential factor in the realisation of the objectives of this Agreement as laid down in Article 1. This cooperation can take financial and non-financial forms.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Project Implementation 2. The Borrower shall:

Time is Money Join Law Insider Premium to draft better contracts faster.